Print

Print


  Gail D. Zeevalk  a,   , Roozbeh Razmpour  b, Laura P. Bernard  a
  a University of Medicine and Dentistry of New Jersey, Robert Wood Johnson 
Medical School, Department of Neurology, Building UBHC, Room 405, 675 Hoes 
Lane, Piscataway, NJ 08854, USA 
  b Johns Hopkins University, Department of Biological Sciences, Baltimore, MD 
21218, USA 

   Abstract
  At least 2 decades have past since the demonstration of a 40–50% deficit in 
total glutathione (GSH) levels in the substantia nigra in patients with 
Parkinson's disease (PD). The similar loss of GSH in the nigra in Incidental 
Lewy body disease, thought to be an early form of PD, indicates that this is 
one of the earliest derangements to occur in the pre-symptomatic stages of 
PD. Oxidative damage to lipids, protein and DNA in the nigra of PD patients 
is consistent with the loss of the antioxidant functions contributed by GSH. 
Past clinical trials that have used an antioxidant approach to treatment have 
used antioxidants that might substitute for GSH but these have shown modest 
to little benefit. More recent studies of the functions served by GSH in 
cells include in addition to its well-known participation in H2 O2 and toxin 
removal, such roles as modulation of protein function via thiolation which 
may control physiological and pathophysiological pathways to include DNA 
synthesis and repair, protein synthesis, amino acid transport, modulation of 
glutamate receptors and neurohormonal signaling. These multifunctional 
aspects to the workings of GSH in the cell would suggest that its loss 
perturbs many different processes and that replenishment and maintenance of 
GSH per se may be the best approach for preventing progressive damage from 
occurring. Despite this, few studies have been directed at specifically 
restoring GSH, although, as discussed herein, its unsanctioned use in PD is 
growing in popularity. This review will focus on glutathione in PD; the 
various functions carried out by glutathione and possible consequences of its 
depletion, as well as measures to elevate GSH in the CNS and its use in 
humans. Consideration of how the CNS generates and handles the substrates for 
GSH synthesis is also addressed with the view in mind that this may provide 
insights into control and maintenance of intracellular glutathione.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn